Overview

* Beyond Air ( XAIR ) fiscal Q2 revenue rises 128% YoY to $1.8 mln, driven by LungFit PH demand

* Net loss and operating loss for Q2 missed analyst expectations

* Company updates fiscal 2026 revenue guidance to $8-$10 mln

Outlook

* Beyond Air ( XAIR ) updates fiscal 2026 revenue guidance to $8-10 mln

* Company anticipates FDA approval of second-gen LungFit PH by end of 2026

* Recent capital infusion to support commercial and regulatory initiatives

Result Drivers

* LUNGFIT PH DEMAND - Revenue growth driven by increased demand for LungFit PH in the U.S.

* GLOBAL EXPANSION - International revenue growth supported by new distribution agreements in multiple countries

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$1.25

Q2 Net Miss -$8.26 -$6.80

Income mln mln (4

Analysts

)

Q2 Miss -$7.66 -$7 mln

Operatin mln (4

g Income Analysts

)

Q2 Gross -$298,00

Profit 0

Q2 -$7.36

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Beyond Air Inc ( XAIR ) is $11.50, about 84.7% above its November 7 closing price of $1.76

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)